ArticleJournal of gastrointestinal cancer2022
Port-Site Metastases in Incidentally Detected Carcinoma Gall Bladder: Role of 18F-FDG PET/CT and Patient Outcome.
Article in Journal of gastrointestinal cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- New trends in diagnosis and management of gallbladder carcinoma.World journal of gastrointestinal oncology · 2024Review
- Antigallbladder Carcinoma Activity Analysis of a New Nanometer Drug Delivery System Based on Data Acquisition.Contrast media & molecular imaging · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncidentally detected gall bladder carcinoma (IGBC) is occasionally encountered after cholecystectomy for benign gall bladder disease. Rarely these patients may present with port-site metastases (PSM) in follow-up. We retrospectively assessed the role of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) in them. We aimed to determine the clinical outcome and correlate the survival based on FDG PET/CT findings. MATERIAL AND
methodWe did a single-center retrospective study in IGBC patients presented with histopathologically proven PSM. FDG PET/CT was done for restaging. The metastatic burden was evaluated. Survival after PSM and overall survival (OS) were assessed in different disease groups.
resultsA total of 22 patients (51.86 ± 12.04 years) were included in the study. The mean interval between LC and PSM was 336.7 ± 501.9 days. On FDG PET/CT, isolated single PSM was noted in 21 (95.5%) patients. Apart from PSM, abdominal lymph nodes, GB fossa lesion, and liver metastases were noted in the 10 (45.5%), 6 ( 27.3%), and 7 (31.8%) patients, respectively. FDG PET/CT revealed intra-abdominal disease and visceral metastasis in 11 (50%) and 10 (45.5%) patients. Nineteen (86.4%) patients died in follow-up with a median survival of 328.50 (225.25-804.0) day after PSM. Median OS after LC was 687.00 (362.50-1047.0) days. Patients with PSM plus disease (432.0 days, 255.9-608.1), extra-abdominal metastases (400.0 days, 316.9-483.1), and visceral metastases (400.0 days, 296.2-503.8) had significantly lower OS compared to isolated PSM (1763 days, p = 0.013), the intra-abdominal disease (996.0 days, 753.2-1238.8, p = 0.0340), and non visceral metastasis (807.0 days, 467.5-1146.4, p = 0.037). IGBC presenting as PSM is a distinct clinical entity. FDG PET/CT as functional imaging evaluates the local and metastatic disease burden. There is significantly lower survival in patients with PSM plus disease, extra-abdominal metastases, or visceral metastases. FDG PET/CT was an important prognostic marker in these patients and could help in management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.